Zeidner, Joshua F.
https://orcid.org/0000-0002-9014-1514
Mayo Clinic
University of North Carolina at Chapel Hill
Citations 22
Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus “7+3” for adults with newly diagnosed acute myeloid leukemia (AML).
Litzow, Mark R. , Morris, Lawrence E. , Levy, Moshe , Gojo, Ivana , Gocke, Christopher D. , Rosner, Gary L. , Greer, Jacqueline M., Cain, Joan McFadden, Little, Richard F. , Wright, John Joseph, Doyle, L. Austin, Karp, Judith E. , Zeidner, Joshua F. , Foster, Matthew C , Blackford, Amanda , Strickland, Stephen Anthony , Lancet, Jeffrey E. , Bose, Prithviraj , Tibes, Raoul , Smith, B. Douglas
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7002-7002
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
Swords, Ronan , Maris, Michael B., Zeidner, Joshua F. , Foran, James M. , Cruz, José C. , Tam, Wayne , Vardhanabhuti, Saran , Pawlikowska-Dobler, Iwona , Faessel, Hélène M. , Dash, Ajeeta B. , Sedarati, Farhad , Dezube, Bruce J., Faller, Douglas V. , Swords, Ronan T , Zeidner, Joshua F , Cruz, Jose , Tam, Wayne , Vardhanabhuti, Saran , Pawlikowska-Dobler, Iwona , Dash, Ajeeta B , Sedarati, Farhad , Faller, Douglas V , Savona, Michael R , Coutré, Steven , Erba, Harry Paul , Berdeja, Jesús G. , Savona, Michael R.
Blood | January 18, 2018 | Volume: 131 | Issue: 13 | Pages: 1415-1424
Key Points RP2D of PEV 20 mg/m2 in PEV/AZA combo did not alter toxicity profile of AZA; dose-limiting toxicities were transiently elevated AST/ALT. In treatment-naive older AML patients, the intent-to-treat ORR was 50%.